@article{ref1,
title="Costing analysis of a point-of-care drug checking program in Rhode Island",
journal="Drug and alcohol dependence",
year="2023",
author="Cepeda, Javier A. and Thompson, Erin and Ujeneza, Merci and Tardif, Jessica and Walsh, Thomas and Morales, Alexis and Rosen, Joseph G. and Green, Traci C. and Park, Ju Nyeong",
volume="253",
number="",
pages="e111028-e111028",
abstract="BACKGROUND: Drug checking is a harm reduction strategy that provides greater awareness and information about the drug supply to the community. While fentanyl test strips are low-cost and available in most parts of the U.S., community-based organizations are considering using more sophisticated technologies, such as Fourier-transform infrared (FTIR) spectroscopy to test drugs. FTIR can detect multiple substances in a non-destructive manner that can be rapidly communicated to the program client by a trained technician, however implementation costs in community-based settings have not been assessed. <br><br>METHODS: We conducted a costing analysis of a new pilot drug checking service that employed an FTIR spectrometer, fentanyl test strips and confirmatory testing in Rhode Island from January 2023-May 2023. We used microcosting methods to determine the overall cost during this period and cost per drug checked, reflecting realistic service capacity. <br><br>RESULTS: Among 101 drug samples that were voluntarily submitted and tested, 53% tested positive for fentanyl, 39% for cocaine, 9% for methamphetamine and 13% for xylazine, a powerful sedative. The total cost during this period was $71,044 and the cost per drug checked was $474, though sensitivity analyses indicated that the cost would rise to $78,058 - $83,058 or $544 - $593 for programs needing to pay for specialized training. <br><br>CONCLUSIONS: These findings demonstrate feasibility and inform the resources needed to scale-up drug checking services to reduce overdose risk.<p /> <p>Language: en</p>",
language="en",
issn="0376-8716",
doi="10.1016/j.drugalcdep.2023.111028",
url="http://dx.doi.org/10.1016/j.drugalcdep.2023.111028"
}